The STR1VE study (AVXS-101-CL-303) was an open-label, multicenter phase III study of onasemnogene abeparvovec in infants with SMA type 1 aged up to 6 months who had up to two copies of SMN2 gene (58). This evidence concerns the gene SMN2 and spinal muscular atrophy, type 1.